RFP QuestBeta
ClosedStage · tender

Ministry of Defence, Defence Science and Technology Laboratory

The Development, Validation and Supply of Physostigmine Free Base

Medical Equipment & PharmaCPV 33661700
Value£10.0m
Deadline28 Apr 2023
Published28 Mar 2023
RegionNationwide
Timeline
Published 28 Mar 2023ClosedCloses 28 Apr 2023
Who to contact
Attn: ADP Procurement
ADPProcurement@dstl.gov.uk

The procurement contact named on the official notice.

How to submit
Open the submissions portal

The submission route named on the official notice.

Contract value in context
£10.0mtotal contract value
median £123k
this tender£0£16.5m

This is a large award for Medical Equipment & Pharmaceuticals — above three-quarters of comparable contracts. Based on 9,456 valued Medical Equipment & Pharmaceuticals tenders in our corpus.

Match for your company
Sign up free to see how well this tender matches your company — the score, the signals that align, and where the gaps are.
The brief

The Ministry of Defence (MoD) is inviting expressions of interest for a requirement for the provision of Physostigmine Free Base(also known as eserine; chemical name 1,2,3,3aβ,8,8aβ-hexahydro-1,3a,8-trimethylpyrrolo[2,3-b] indol-5-yl-methylcarbamate; chemical formula C15H21N3O2; molecular weight 275,36 g/mol). as part of an ongoing product development and anticipated commercialisation.

The initial Physostigmine supplied must be suitable for use in a pivotal Phase I clinical setting and the manufacturing process will produce material which does not add additional non-clinical activities to the overall programme, best endeavours should be taken to remove processing impurities.

The Supplier is to develop, scale-up and validate the manufacturing method for Physostigmine Free Base as an Active Pharmaceutical Ingredient (API) for use in a MoD final medicinal product currently under development.

The API must be developed and manufactured according to Good Manufacturing Practice (GMP) and must conform to European Transmissible Spongiform Encephalopathies (TSE) requirements, developed such that Intellectual property (IP) is vested in the Authority.

The Authority intends to seek a Marketing Authorisation for the final medicinal product from the Medicines and Healthcare products Regulatory Agency (MHRA) and Physostigmine will be required as an active ingredient for a future registered medicinal product.

The Supplier is required to provide information necessary for the Authority to complete the Chemistry, Manufacturing and Control (CMC) documentation to support a Clinical Trial Application (CTA) and Marketing Authorisation Application for the final medicinal product and make this documentation available to the MA applicant in an appropriate format for inclusion within CTD Module 3.

The Authority anticipates a Limited Quality by Design (QBD) approach to the manufacturing process as defined by the International Conference on Harmonisation (ICH).

All procurement documents are accessible via www.contracts.mod.uk Quantity or scope: The Contract has an expected duration of 10 years (120 months), plus 5 option years (60 months).

Option years may be taken up consecutively or concurrently (to be determined).

Key requirements

What the supplier must deliver

01

The initial Physostigmine supplied must be suitable

The initial Physostigmine supplied must be suitable for use in a pivotal Phase I clinical setting and the manufacturing process will produce material which does not add additional non-clinical activities to the overall programme, best endeavours should be taken to remove processing impurities.

02

The API must be developed and manufactured

The API must be developed and manufactured according to Good Manufacturing Practice (GMP) and must conform to European Transmissible Spongiform Encephalopathies (TSE) requirements, developed such that Intellectual property (IP) is vested in the Authority.

Derived from the notice text — always confirm against the original documents.

Buyer intelligence

Make the case to bid

Reveal who to approach at Ministry of Defence, Defence Science and Technology Laboratory, and generate a go-to-market strategy from their news, accounts and people.

Deep dive · beta

The full intelligence dossier

Our agent reads Ministry of Defence, Defence Science and Technology Laboratory’s accounts, hunts live signals, finds the people who decide — and hands you a bid strategy plus a go-to-market influence plan, including what your team should post this week. You approve every paid step.

Source & provenance
OCID
ocds-h6vhtk-03b6c1
Stage
tender · Open
Source
Find a Tender
Buyer ref
009030-2023
View the original notice on Find a Tender

Contains public sector information licensed under the Open Government Licence v3.0. Source data © Crown copyright.

Market context

Who wins this kind of work

The suppliers and buyers around this opportunity — drawn from official award data. Drag to orbit; click a node to explore.

Top suppliers & buyers in Medical Equipment & Pharmaceuticals

Scroll to explore the market network

Ministry of Defence, Defence Science and Technology Laboratory’s tender network

Assembling the network…

Also open now

Similar open tenders

Supply of Wheelchairs, Associated Parts and Accessories - anual Paediatric Postural Advanced Wheelchair

NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust)

Closes 21 Aug 2026Medical Equipment & Pharma
£359kValue

Functional Electrical Stimulation Supplies and Maintenance

Procurement Assist Limited c/o Integrated Facilities Management Bolton Ltd (iFM Bolton)

Closes 31 May 2029Medical Equipment & Pharma
£50.0mValue